All Pathways
GastroenterologyManagement

Acute Biliary Pancreatitis - GI Management (ACG 2024)

Acute Biliary Pancreatitis - GI Management (ACG 2024): Acute Biliary Pancreatitis Diagnosed → Assess Severity & Cholangitis → Concomitant Cholangitis? →...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Acute Biliary Pancreatitis Diagnosed

    Pancreatitis + gallstones/biliary sludge on imaging

    1. Action

      Assess Severity & Cholangitis

      Key decision points for ERCP

      • BISAP, APACHE II, or Ranson's score
      • Signs of cholangitis: fever, RUQ pain, jaundice (Charcot's)
      • Worsening LFTs (especially bilirubin)
      • CBD dilation on imaging (>6mm or >8mm if post-CCY)
      1. Decision

        Concomitant Cholangitis?

        Tokyo Guidelines criteria

        1. Warning

          ⚠️ Urgent/Emergent ERCP

          Within 24 hours (ideally <12h if sepsis)

          • Definite cholangitis = ERCP within 24 hours
          • Severe cholangitis/sepsis = <12 hours
          • Sphincterotomy + stone extraction
          • Biliary stent if unable to clear duct
          1. Decision

            Pancreatitis Resolving?

            Pain improving, tolerating diet, normalizing labs

            1. Action

              Same-Admission Cholecystectomy

              STRONGLY recommended for mild biliary pancreatitis

              • Reduces recurrent pancreatitis by 75%
              • Perform before discharge if mild disease
              • Laparoscopic preferred
              • IOC to confirm CBD clear
              • Delay only if severe pancreatitis/local complications
              1. Outcome

                Biliary Pancreatitis Resolved

                CCY done, biliary tract cleared - no further intervention needed

            2. Action

              Severe Pancreatitis - Delayed CCY

              Wait for local complications to resolve

              • Delay 6+ weeks if necrosis/collections
              • Interval cholecystectomy when recovered
              • High recurrence risk if CCY not done (~30-50%)
              1. Outcome

                Outpatient Follow-up

                Schedule cholecystectomy within 2-6 weeks if not done inpatient

        2. Decision

          Persistent CBD Obstruction?

          Elevated bili, dilated CBD without cholangitis

          1. Action

            CBD Stone Probability Assessment

            Risk stratification for CBD stone

            • High risk: CBD stone on US, cholangitis, bili >4
            • Intermediate: CBD dilation, bili 1.8-4, abnormal LFTs
            • Low risk: normal labs and no CBD dilation
            1. Action

              High Risk → ERCP

              Direct to ERCP without further imaging

              • ERCP within 24-72 hours
              • Sphincterotomy + stone extraction
              • No need for MRCP/EUS first
            2. Action

              Intermediate Risk → MRCP/EUS

              Further imaging to confirm CBD stone

              • MRCP or EUS preferred (non-invasive)
              • Sensitivity ~95% for CBD stones
              • ERCP if stone confirmed
              • Avoid unnecessary ERCP (PEP risk)
            3. Action

              Low Risk → Observe

              No ERCP, proceed to cholecystectomy

              • Labs normalizing
              • No CBD dilation
              • ERCP NOT indicated for all biliary pancreatitis
              • IOC at time of cholecystectomy

Guideline Source

ACG Clinical Guideline: Acute Pancreatitis 2024

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • ERCP timing is critical and evolving
  • Cholangitis determination requires clinical judgment
  • MRCP availability may delay diagnosis
  • Same-admission cholecystectomy requires surgical coordination

Applicable Regions

USEUGlobal

EU: Similar to IAP/APA guidelines

US: ACG 2024 is current standard

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Acute Biliary Pancreatitis - GI Management (ACG 2024)?

The Acute Biliary Pancreatitis - GI Management (ACG 2024) is a management clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on ACG Clinical Guideline: Acute Pancreatitis 2024.

What guideline is the Acute Biliary Pancreatitis - GI Management (ACG 2024) based on?

This algorithm is based on ACG Clinical Guideline: Acute Pancreatitis 2024 (DOI: 10.14309/ajg.0000000000002645).

What are the limitations of the Acute Biliary Pancreatitis - GI Management (ACG 2024)?

Known limitations include: ERCP timing is critical and evolving; Cholangitis determination requires clinical judgment; MRCP availability may delay diagnosis; Same-admission cholecystectomy requires surgical coordination. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Acute Biliary Pancreatitis - GI Management (ACG 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free